Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 13/20 | 0.57 |
| ▸ | CA12 | O43570 | 12/20 | 0.56 |
| ▸ | CA1 | P00915 | 11/20 | 0.56 |
| ▸ | CA9 | Q16790 | 10/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA5A | P35218 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475784 | 1.00 | CYP2D6 (0.63) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL12732788 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL13901312 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL223457 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL12942109 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL23266161 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL13410454 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL21945978 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL22330671 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 | |
| SCHEMBL7151976 | 0.85 | CYP2D6 (0.73) | CYP2D6THRBHSD17B10CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373285-A4 | SYNTHESIS AND USE OF GLYCODENDRIMER REAGENTS | GENENCOR INT (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2006055644-A2 | SYNTHESIS AND USE OF GLYCODENDRIMER REAGENTS | GENENCOR INTERNATIONAL, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20050272670-A1 | Synthesis and use of glycodendrimer reagents | DAVIS BENJAMIN G | 2005-12-08 | — | — | US | disclosed |
| EP-1373285-A2 | SYNTHESIS AND USE OF GLYCODENDRIMER REAGENTS | GENENCOR INTERNATIONAL, INC. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6627744-B2 | A chemically modified mutant protein, e.g. an enzyme, having a substituted cysteine reacted with a glyosyslated thiosulfate; high esterase activity and low amidase activity of subtilisins; protease to degrade lectins | GENENCOR INTERNATIONAL, INC. | 2003-09-30 | — | — | US | disclosed |
| WO-2002079394-A2 | SYNTHESIS AND USE OF GLYCODENDRIMER REAGENTS | GENENCOR INTERNATIONAL, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020019039-A1 | Synthesis and use of glycodendrimer reagents | GENENCOR INTERNATIONAL, INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019039-A1 | Synthesis and use of glycodendrimer reagents | STT3A, STT3B, PTMS | CYP2D6 1808/4885THRB 3866/4885HSD17B10 2809/4885 |
| US-20050272670-A1 | Synthesis and use of glycodendrimer reagents | STT3A, PTMS, STT3B | CYP2D6 1974/4885THRB 3941/4885HSD17B10 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.